Drug Pricing
The Trump administration and state governments are taking action on drug pricing. Keep up with our comprehensive coverage of administrative and legislative activity and what it means for industry, plans, providers, and patients.
Featured Content
Summary: What’s on the Horizon for US Drug Pricing Policy in 2019 and Beyond?
On October 25, Avalere experts came together to discuss the latest policy developments related to drugs.
Webinar: Drug Pricing Policy: What’s on the Horizon?
Avalere experts examine the current drug pricing policy landscape and what potential changes stakeholders should prepare for.
Key Considerations for Medicare Advantage Plans Evaluating New Part B Step Therapy Flexibility
Following its recent announcement to grant Medicare Advantage (MA) plans the flexibility to use step therapy techniques for Part B drugs beginning in January 2019, the Centers for Medicare & Medicaid Services (CMS) released an FAQ with additional guidance on its implementation.
CMS Announces New Flexibilities in Medicare Part D
Under an indication-based formulary design approach, Part D plans will be able to tailor the drugs that are on their formulary by indication.
Eliminating Drug Rebates Requires Complex Solutions
Reforms to “eliminate rebates” could have varying impacts based on features of their design.
CMS Grants Medicare Advantage Plans Flexibility to Use Step Therapy for Part B Drugs
Beginning in January 2019, Medicare Advantage (MA) plans will have the flexibility to use step-therapy techniques for Part B drugs, according to a CMS memo released on August 7.
Avalere Analysis Highlights Complexities of Transitioning Medicare Part B Drugs into Part D
Moving certain Part B drugs to Part D, a proposal being evaluated by the Trump administration, would have disparate financial impacts on patients.
The Complexities of Transitioning Medicare Part B Drugs into Part D
Moving certain Part B drugs to Part D, a proposal being evaluated by the Trump administration, would have disparate financial impacts on patients.
Trump Administration Releases Drug Pricing Blueprint
The Department of Health and Human Services is seeking public input on a variety of proposals related to drug costs, providing stakeholders with an unprecedented opportunity to shape the administration's drug pricing policies.
Recent Proposals by the Administration Hint at Areas of Focus for Upcoming Drug Pricing Plan
President Trump is expected to announce a drug pricing plan in the coming weeks; signals from the White House indicate potential alignment around several priority policies.
The Seven Types of Drug Pricing Legislation to Watch
Increasingly, states are taking steps to control prescription drug spending and prices.
Payer Trends in Oncology
The shift from volume to value has played a significant role in shaping current payer behavior in the oncology space.
Biosimilars Gain Widespread Adoption by Health Plans
New research from Avalere finds that most health plans are covering at least one of the two biosimilar products currently on the market.
Webinar: Drug Pricing: Where’s the Future Headed?
Avalere experts review proposed drug pricing policies from each stakeholder's perspective across the industry and the implications each might carry.
